<p><strong>来自 ALOHA 计划和 NU-GEN™细胞更新精华的数据显示有助于推动实践成功</strong></p>
<p>纽约，2026 年 5 月 15 日（GLOBE NEWSWIRE）——Obagi Medical 是一家领先的医生分销护肤和美学解决方案的创新公司，隶属于 Waldencast plc（纳斯达克：WALD），今天宣布在 5 月 13 日至 17 日在田纳西州纳什维尔举行的音乐城 SCALE 会议上分享的新数据。</p>
<ul>
<li>一项为期 12 周的开放标签研究结果，评估 Obagi NU-GEN 细胞更新精华对皱纹、色素沉着、光泽、质地、紧致度、饱满度和感知皮肤年龄的疗效和耐受性：ePoster Dr. Todd Schlessinger, MD</li>
<li>一项大规模多位医生的真实世界评估的中期结果，评估一种新型透明质酸皮肤填充剂与医用级护肤品结合使用的效果：ePoster Dr. Carolyn Jacob, MD</li>
</ul>
<p>“作为 FDA 注册项目中 Obagi 填充剂的关键临床站点之一，我对 Obagi Saypha® MagIQ™的真实世界评估感到非常感兴趣，” Dr. Carolyn Jacob, MD 表示。“审查来自 300 多个参与站点的结果验证了核心临床结果，并明确表明 MagIQ 在大多数实践中都有其位置。”</p>
<p>真实世界数据评估了 ALOHA（与 Obagi 透明质酸的美学领导力）计划的中期审查，这是一个旨在通过实践主导的洞察加速美学创新的结构化临床合作计划。Obagi 预计 ALOHA 计划将成为新的可注射填充剂的最大真实世界评估计划。中期数据突显出 94% 的注射者认为 Obagi Saypha® MagIQ™补充了他们当前的填充剂选择，并显示 43% 的患者也在评估 Obagi 护肤品。</p>
<p>“这些数据点代表了我们最新 Obagi 创新的临床和真实世界结果，” 美国专业渠道总经理 Drew Fine 表示。“Obagi Saypha® MagIQ™和 NU-GEN™细胞更新精华代表了支持实践成功的重要进展，并突显了关注 Obagi 可注射和护肤解决方案的好处。”</p>
<p>该 ePoster 代表了 NU-GEN 临床项目的首次数据分享。该配方经过临床验证，能够通过帮助补充 NAD+ 并同时解决九种皮肤老化迹象，显著逆转皮肤年龄达六年 1。</p>
<p><strong>关于 Obagi Medical</strong></p>
<p>Obagi Medical 是一家行业领先的先进护肤品牌，根植于研究和皮肤生物学，拥有超过 35 年的经验。最初以其在 Obagi Nu-Derm®系统中治疗色素沉着的领导地位而闻名，Obagi Medical 产品旨在解决多种皮肤问题，包括早衰、光损伤、皮肤色素沉着、痤疮和阳光损伤。作为 2024 年美国增长最快的专业护肤品牌，Obagi Medical 使个人能够实现健康、美丽的肌肤。有关 Obagi Medical 的更多信息，请访问品牌网站，<strong>https://www.obagi.com</strong>。</p>
<p><strong>关于 Waldencast plc</strong></p>
<p>Waldencast 由 Michel Brousset 和 Hind Sebti 创立，其雄心是通过开发、收购、加速和扩展有意识的、高增长的目标驱动品牌，建立全球一流的美容和健康运营平台。Waldencast 的愿景根本上基于其品牌主导的商业模式，确保与客户的紧密联系、业务灵活性和市场响应能力，同时保持每个品牌的独特 DNA。实现其愿景的第一步是商业合并。作为 Waldencast 平台的一部分，其品牌将受益于多品牌平台的运营规模；在大规模管理全球美容品牌方面的专业知识；平衡的投资组合以减轻类别波动；轻资产效率；以及创业独立品牌的市场响应能力和速度。有关更多信息，请访问：<strong>https://ir.waldencast.com</strong>。</p>
<p><strong>媒体联系：</strong></p>
<p>obagi@behrmancesa.com</p>
<p>1 结果基于 2025 年为期 12 周的衰老临床测试。个体结果可能有所不同。数据存档于 Obagi Cosmeceuticals LLC。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1EWTNOQ00zTmpBME5UQTNJekl5TWpVek5EWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1EWTNOQ00zTmpBME5UQTNJekl5TWpVek5EWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png"/></p>

WALD

<p>Obagi Medical 在音乐城 SCALE 会议上展示了新数据，展示其 NU-GEN 细胞更新精华和 Obagi Saypha® MagIQ™ 皮肤填充剂的有效性。ALOHA 计划的中期结果显示，94% 的注射医生认为 MagIQ™ 补充了他们当前的产品，43% 的患者也考虑使用 Obagi 护肤品。NU-GEN 精华在临床上证明能够减少可见的衰老迹象。Obagi Medical 旨在通过创新的护肤解决方案提升实践成功率</p>

<p><strong>Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success</strong></p>
<div class="lb-trans"><p><strong>来自 ALOHA 计划和 NU-GEN™细胞更新精华的数据显示有助于推动实践成功</strong></p>
</div><p>NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the Music City SCALE meeting taking place May 13-17 in Nashville, TN.</p>
<div class="lb-trans"><p>纽约，2026 年 5 月 15 日（GLOBE NEWSWIRE）——Obagi Medical 是一家领先的医生分销护肤和美学解决方案的创新公司，隶属于 Waldencast plc（纳斯达克：WALD），今天宣布在 5 月 13 日至 17 日在田纳西州纳什维尔举行的音乐城 SCALE 会议上分享的新数据。</p>
</div><ul>
<li>Results from a 12-Week Open-Label Study Evaluating the Efficacy and Tolerability of Obagi NU-GEN Cellular Renewal Serum on Wrinkles, Hyperpigmentation, Radiance, Texture, Firmness, Plumpness, and Perceived Skin Age: ePoster Dr. Todd Schlessinger, MD</li>
<li>Interim Results from a large scale Multiple Practitioner Real-World Evaluation of a Novel Hyaluronic Acid Dermal Filler in Conjunction with Medical Grade Skin Care: ePoster Dr. Carolyn Jacob, MD</li>
</ul>
<div class="lb-trans"><ul>
<li>一项为期 12 周的开放标签研究结果，评估 Obagi NU-GEN 细胞更新精华对皱纹、色素沉着、光泽、质地、紧致度、饱满度和感知皮肤年龄的疗效和耐受性：ePoster Dr. Todd Schlessinger, MD</li>
<li>一项大规模多位医生的真实世界评估的中期结果，评估一种新型透明质酸皮肤填充剂与医用级护肤品结合使用的效果：ePoster Dr. Carolyn Jacob, MD</li>
</ul>
</div><p>“As one of the pivotal clinical sites for the FDA registration programs for the Obagi fillers, I was intrigued to do a real-world evaluation of Obagi Saypha® MagIQ™,” said Dr. Carolyn Jacob, MD. “Reviewing the results from over 300 participating sites validated the core clinical results and makes it clear that there is a place for MagIQ in most practices.”</p>
<div class="lb-trans"><p>“作为 FDA 注册项目中 Obagi 填充剂的关键临床站点之一，我对 Obagi Saypha® MagIQ™的真实世界评估感到非常感兴趣，” Dr. Carolyn Jacob, MD 表示。“审查来自 300 多个参与站点的结果验证了核心临床结果，并明确表明 MagIQ 在大多数实践中都有其位置。”</p>
</div><p>The real-world data evaluated an interim review of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program, a structured clinical collaboration program designed to accelerate aesthetic innovation through practice-led insight. Obagi anticipates that the ALOHA program will become the largest real-world evaluation program for a new injectable filler. The interim data highlights that 94% of injectors believe Obagi Saypha® MagIQ™ compliments their current filler options and shows 43% of patients also evaluating Obagi skincare.</p>
<div class="lb-trans"><p>真实世界数据评估了 ALOHA（与 Obagi 透明质酸的美学领导力）计划的中期审查，这是一个旨在通过实践主导的洞察加速美学创新的结构化临床合作计划。Obagi 预计 ALOHA 计划将成为新的可注射填充剂的最大真实世界评估计划。中期数据突显出 94% 的注射者认为 Obagi Saypha® MagIQ™补充了他们当前的填充剂选择，并显示 43% 的患者也在评估 Obagi 护肤品。</p>
</div><p>“These data points represent clinical and real-world results from our newest Obagi innovations,” stated Drew Fine, U.S. General Manager, Professional Channel. “Obagi Saypha® MagIQ™ and NU-GEN™ Cellular Renewal Serum represent meaningful advances that support practice success and highlight the benefits of looking at Obagi injectable and skincare solutions.”</p>
<div class="lb-trans"><p>“这些数据点代表了我们最新 Obagi 创新的临床和真实世界结果，” 美国专业渠道总经理 Drew Fine 表示。“Obagi Saypha® MagIQ™和 NU-GEN™细胞更新精华代表了支持实践成功的重要进展，并突显了关注 Obagi 可注射和护肤解决方案的好处。”</p>
</div><p>The ePoster represents the first data sharing from the NU-GEN clinical program. The formula is clinically proven to visibly rewind skin’s age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously.</p>
<div class="lb-trans"><p>该 ePoster 代表了 NU-GEN 临床项目的首次数据分享。该配方经过临床验证，能够通过帮助补充 NAD+ 并同时解决九种皮肤老化迹象，显著逆转皮肤年龄达六年 1。</p>
</div><p><strong>About Obagi Medical</strong></p>
<div class="lb-trans"><p><strong>关于 Obagi Medical</strong></p>
</div><p>Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, <strong>https://www.obagi.com</strong>.</p>
<div class="lb-trans"><p>Obagi Medical 是一家行业领先的先进护肤品牌，根植于研究和皮肤生物学，拥有超过 35 年的经验。最初以其在 Obagi Nu-Derm®系统中治疗色素沉着的领导地位而闻名，Obagi Medical 产品旨在解决多种皮肤问题，包括早衰、光损伤、皮肤色素沉着、痤疮和阳光损伤。作为 2024 年美国增长最快的专业护肤品牌，Obagi Medical 使个人能够实现健康、美丽的肌肤。有关 Obagi Medical 的更多信息，请访问品牌网站，<strong>https://www.obagi.com</strong>。</p>
</div><p><strong>About Waldencast plc</strong></p>
<div class="lb-trans"><p><strong>关于 Waldencast plc</strong></p>
</div><p>Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: <strong>https://ir.waldencast.com</strong>.</p>
<div class="lb-trans"><p>Waldencast 由 Michel Brousset 和 Hind Sebti 创立，其雄心是通过开发、收购、加速和扩展有意识的、高增长的目标驱动品牌，建立全球一流的美容和健康运营平台。Waldencast 的愿景根本上基于其品牌主导的商业模式，确保与客户的紧密联系、业务灵活性和市场响应能力，同时保持每个品牌的独特 DNA。实现其愿景的第一步是商业合并。作为 Waldencast 平台的一部分，其品牌将受益于多品牌平台的运营规模；在大规模管理全球美容品牌方面的专业知识；平衡的投资组合以减轻类别波动；轻资产效率；以及创业独立品牌的市场响应能力和速度。有关更多信息，请访问：<strong>https://ir.waldencast.com</strong>。</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系：</strong></p>
</div><p>obagi@behrmancesa.com</p>
<div class="lb-trans"><p>obagi@behrmancesa.com</p>
</div><p>1 Results based on a 2025 12-week aging clinical test. Individual results may vary. Data on file at Obagi Cosmeceuticals LLC.</p>
<div class="lb-trans"><p>1 结果基于 2025 年为期 12 周的衰老临床测试。个体结果可能有所不同。数据存档于 Obagi Cosmeceuticals LLC。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1EWTNOQ00zTmpBME5UQTNJekl5TWpVek5EWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMDY3NCM3NjA0NTA3IzIyMjUzNDY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGVlNWU4MjYtYzMzMS00MGQxLThmMDYtYjhkYmIxMjZmODMzLTEyMzY4OTktMjAyNi0wNS0xNS1lbg==/tiny/Waldencast-plc-.png"/></p>

Obagi Medical 在音乐之城美容进步与激光教育研讨会（SCALE）会议上分享了关于近期创新的新数据 | WALD 股票新闻